Most Popular
-
1
Now is no time to add pressure on businesses: top executives
-
2
CJ CheilJedang to spur overseas growth with new Hungary, US plants
-
3
Seoul to host winter festival from Dec. 13
-
4
Nationwide rail disruptions feared as union plans strike from Dec. 5
-
5
Blackpink's solo journeys: Complementary paths, not competition
-
6
N. Korea, Russia court softer image: From animal diplomacy to tourism
-
7
[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts
![[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050099_0.jpg&u=20241121172748)
-
8
Smugglers caught disguising 230 tons of Chinese black beans as diesel exhaust fluid
-
9
Korean Air offers special flights for mileage users
-
10
Defense ministry denies special treatment for BTS’ V amid phone use allegations
![[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050099_0.jpg&u=20241121172748)
Bukwang Pharmaceutical attains license to sell Denmark’s anti-cancer drug
By Ahn Sung-miPublished : June 30, 2016 - 16:14
[THE INVESTOR] Bukwang Pharmaceutical ’s subsidiary Dyna Therapeutics has clinched a deal with Denmark’s Solural Pharma for its new anti-cancer drug, the company said on June 30.
Dyna Therapeutic attained the exclusive rights to develop and sell SOL-804, which is used for the treatment of castration-resistant prostate cancer, around the world.
By Ahn Sung-mi (sahn@heraldcorp.com)
![[Today’s K-pop] Babymonster logs 100m views with ‘Drip’ music video](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=642&simg=/content/image/2024/11/22/20241122050051_0.jpg&u=20241122172213)